

Edgar Filing: BIOENVISION INC - Form SC 13D

BIOENVISION INC  
Form SC 13D  
April 04, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BIOENVISION, INC.  
(Name of Issuer)

COMMON STOCK, PAR VALUE \$.001 PER SHARE  
(Title of Class of Securities)

09059N 100  
-----

(CUSIP Number)

Steven H. Rouhandeh  
SCO Capital Partners LLC  
1285 Avenue of the Americas, 35th Floor  
New York, New York 10019  
(212) 554-4158

(Name, Address and Telephone Number of Person Authorized  
to Receive Notices and Communications)

February 1, 2002  
-----

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a  
statement on Schedule 13G to report the acquisition which is the  
subject of this Schedule 13D, and is filing this Schedule  
because of Rule 13d-1(b)(3) or (4), check the following box [ ].

Page 1 of 8 pages

SCHEDULE 13D

-----  
CUSIP No. 808631 10 5  
-----

-----  
PAGE 2 OF 8 PAGES  
-----

-----  
1      NAME OF REPORTING PERSON  
         S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Steven H. Rouhandeh  
-----

Edgar Filing: BIOENVISION INC - Form SC 13D

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) [ ]  
(b) [X]

3 SEC USE ONLY

4 SOURCE OF FUNDS\*

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO  
ITEMS 2(d) or 2(E) [ ]

6 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 7 SOLE VOTING POWER  
SHARES 300,000

BENEFICIALLY 8 SHARED VOTING POWER  
OWNED BY 7,179,946

EACH 9 SOLE DISPOSITIVE POWER  
REPORTING 300,000

PERSON WITH 10 SHARED DISPOSITIVE POWER  
7,179,946

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
7,479,946

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN  
SHARES\* [ ]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
38.86%

14 TYPE OF REPORTING PERSON\*  
IN

\* SEE INSTRUCTIONS BEFORE FILLING OUT!

Edgar Filing: BIOENVISION INC - Form SC 13D

-2-

SCHEDULE 13D

-----  
CUSIP No. 808631 10 5  
-----

-----  
PAGE 3 OF 8 PAGES  
-----

-----  
1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
  
SCO CAPITAL PARTNERS LLC  
-----

-----  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) [ ]  
(b) [X]  
-----

-----  
3 SEC USE ONLY  
-----

-----  
4 SOURCE OF FUNDS\*  
  
OO  
-----

-----  
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO  
ITEMS 2(d) or 2(E) [ ]  
-----

-----  
6 CITIZENSHIP OR PLACE OF ORGANIZATION  
  
Delaware  
-----

-----  
NUMBER OF 7 SOLE VOTING POWER  
SHARES 7,009,946  
-----

-----  
BENEFICIALLY 8 SHARED VOTING POWER  
OWNED BY 470,000  
-----

-----  
EACH 9 SOLE DISPOSITIVE POWER  
REPORTING 7,009,946  
-----

-----  
PERSON WITH 10 SHARED DISPOSITIVE POWER  
470,000  
-----

-----  
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
-----

Edgar Filing: BIOENVISION INC - Form SC 13D

7,479,946

-----  
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN [ ]  
SHARES\*  
-----

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
38.86%  
-----

14 TYPE OF REPORTING PERSON\*  
  
PN  
-----

\* SEE INSTRUCTIONS BEFORE FILLING OUT!

-3-

ITEM 1. SECURITY AND ISSUER.

This statement on Schedule 13D ("Schedule 13D") is being filed with respect to the common stock, par value \$.001 per share (the "Common Stock") of Bioenvision, Inc., a Delaware corporation (the "Company"). The principal executive offices of the Company are located at 509 Madison Avenue, Suite 404, New York, New York 10022.

This Schedule 13D is being filed pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the "Exchange Act").

ITEM 2. IDENTITY AND BACKGROUND.

(a) This Schedule 13D is filed by (i) Steven H. Rouhandeh ("Rouhandeh") and (ii) SCO CAPITAL PARTNERS LLC, a limited liability company organized under the laws of the State of Delaware ("SCO"). Rouhandeh and SCO are collectively referred to herein as the "Reporting Persons."

(b) The Reporting Persons' business address is 1285 Avenue of the Americas, 35th Floor, New York, New York 10019.

(c) The principal business of Rouhandeh is to serve as the Chairman of SCO. The principal business of SCO is to invest in biotechnology companies.

(d) During the last five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Rouhandeh is a United States citizen. SCO is a limited liability company organized under the laws of the State of Delaware.

## Edgar Filing: BIOENVISION INC - Form SC 13D

-4-

### ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

On May 8, 2002, Bioenvision consummated a private placement transaction pursuant to which Bioenvision raised \$17.75 million in equity financing. SCO acted as Bioenvision's financial advisor in connection with this equity offering. As consideration for services rendered, SCO received a warrant to purchase 688,333 shares of Common Stock at an exercise price of \$1.50 per share, and an affiliate of SCO received a warrant to purchase 70,000 shares of Common Stock at an exercise price of \$1.50 per share. The warrants expire five years from the date of issuance. The issuance of these warrants was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act

On February 1, 2002, Bioenvision issued an aggregate of 7,000,000 shares of common stock, par value \$.001 per share (the "Common Stock") to the former stockholders of Pathagon, Inc., in connection with the consummation of a merger transaction. Of this amount, SCO received 5,121,613 shares of Common Stock as consideration in the merger transaction. The issuance of these shares was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act.

On November 16, 2001, Bioenvision and SCO entered into a revolving credit facility pursuant to which Bioenvision could borrow up to \$1 million from SCO. In connection with this revolving credit facility, Bioenvision issued (i) to SCO a warrants to purchase 1,200,000 shares of Common Stock at an exercise price of \$1.25 per share, subject to certain anti-dilution adjustments, and (ii) to each of the Sophie C. Rouhandeh Trust (the "SR Trust") and Chloe H. Rouhandeh Trust (the "CR Trust" and, together with the SR Trust, the "Trusts"), with respect to both of which Rouhandeh, President of SCO, serves as trustee, a warrant to purchase 150,000 shares of Common Stock to an affiliate of SCO at an exercise price of \$1.25 per share. All of the foregoing warrants expire five years from the date of issuance. The issuance of these warrants was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act. As trustee of the Trusts, Rouhandeh has voting power and investment power with respect to these shares, but disclaims any beneficial ownership thereof.

-5-

On November 16, 2001, Bioenvision entered into an engagement letter with SCO pursuant to which SCO acted as Bioenvision's financial advisor. In connection with this engagement letter and services rendered pursuant thereto, Bioenvision issued to SCO Financial Group LLC, an affiliate of SCO, a warrant to purchase 100,000 shares of Common Stock at an exercise price of \$1.25 per share, subject to certain anti-dilution adjustments. The warrant expires five years from the date of issuance. The issuance of this warrant was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act.

### ITEM 4. PURPOSE OF TRANSACTION.

Each of the Reporting Persons purchased their shares of Common Stock for investment purposes. Each of the Reporting Persons may acquire additional shares of Common Stock from time to time, in open market purchases, negotiated transactions or otherwise, and may sell any or all of such shares of Common Stock at any time.

-6-

Other than as set forth in the preceding paragraph of this Item 4, each of the Reporting Persons does not have any plans or proposals which relate to or would result in any of the matters enumerated in clauses (a) through (j), inclusive, of Item 4 of Schedule 13D, namely: (a) the acquisition by any person of additional securities of the Company or the disposition of securities of the Company; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries; (d) any change in the present Board of Directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Board; (e) any material change in the present capitalization or dividend policy of the Company; (f) any other material change in the Company's business or corporate structure; (g) changes in the Company's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any person; (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action similar to any of those enumerated above.

-7-

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

(a) As of the date hereof, (i) each Trust owns a warrant to purchase 150,000 shares of Common Stock, and (ii) SCO owns 5,121,613 shares of Common Stock, and warrants to purchase an aggregate of 2,358,333 shares of Common Stock. In his capacity as Chairman of SCO, Rouhandeh may be deemed beneficially to own the 5,121,613 shares of Common Stock and warrants to purchase 2,358,333 shares of Common Stock owned directly by SCO or an affiliate thereof. Mr. Rouhandeh disclaims beneficial ownership of the shares of Common Stock and warrants held by SCO or an affiliate thereof.

(b) As trustee of each Trust, Rouhandeh has sole power to vote 300,000 shares of Common Stock upon conversion of the warrants held by each of the Trusts. Rouhandeh, in his capacity as President of SCO, has the shared power to direct the vote and disposition of the 5,121,613 shares of Common Stock owned by SCO or an affiliate thereof and, upon conversion of warrants, Rouhandeh has the shared power to direct the vote and disposition of an additional 2,358,333 shares of Common Stock owned by SCO or an affiliate thereof.

(c) Not applicable.

(d) Not applicable.

(e) Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

Reference is made to the Reporting Persons' responses to Item 3.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Edgar Filing: BIOENVISION INC - Form SC 13D

None.

-8-

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: April 4, 2003

/s/ Steven H. Rouhandeh

-----  
Steven H. Rouhandeh

SCO CAPITAL PARTNERS LLC

By: /s/ Steven H. Rouhandeh

-----  
Name: Steven H. Rouhandeh  
Title: Chairman

-9-